HOLDEN, Mass., Sept. 14 /PRNewswire/ -- Today, Hygeia Therapeutics, Inc. (“Hygeia”) announced the appointment of Elkan Gamzu, Ph.D. as Chairman to its Board of Directors. Dr. Gamzu has nearly 40 years of pharmaceutical and biotechnology experience and has held senior executive positions including CEO of Pharmos Corporation, Vice President of Project Management at Millenium Pharmaceuticals, CEO of Cambridge Neuroscience, Vice President of Drug Development at Warner-Lambert, senior research positions at Hoffmann-LaRoche, and most recently, CEO of EPIX Pharmaceuticals.
“I am honored to accept this position with Hygeia, especially given the tremendous potential of the pipeline to develop products that can greatly improve the quality of life of patients, while minimizing the risk,” said Dr. Gamzu.
About Hygeia Therapeutics, Inc.
Hygeia acquires and develops biodegradable hormone-receptor modulators for topical indications. Hygeia products are all designed to be rapidly deactivated by enzymes at or near the site of application after the therapeutic effects are achieved. By avoiding the formation of active or toxic metabolites, Hygeia topical drugs are expected to have negligible systemic effects and have a better safety profile than other drugs in their therapeutic class. Hygeia assets were obtained by an exclusive license with Yale University.
Hygeia Therapeutics, Inc.
